Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Fulcrum Therapeutics (NASDAQ:FULC) from a hold rating to a strong-buy rating in a report released on Friday morning,Zacks.com reports.

FULC has been the topic of a number of other research reports. HC Wainwright reiterated a “neutral” rating and set a $4.00 target price on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th. Leerink Partners upgraded Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $12.00 in a research report on Friday. Finally, Cantor Fitzgerald upgraded Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price on the stock in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Fulcrum Therapeutics presently has an average rating of “Hold” and an average target price of $5.83.

Fulcrum Therapeutics Price Performance

Shares of NASDAQ:FULC opened at $6.44 on Friday. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $10.13. The firm has a market capitalization of $347.62 million, a price-to-earnings ratio of -20.77 and a beta of 2.29. The business’s 50 day moving average price is $4.03 and its 200-day moving average price is $3.91.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.01. On average, sell-side analysts expect that Fulcrum Therapeutics will post -0.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC increased its stake in shares of Fulcrum Therapeutics by 865.0% in the 1st quarter. Acadian Asset Management LLC now owns 344,561 shares of the company’s stock worth $989,000 after acquiring an additional 308,854 shares during the last quarter. Jane Street Group LLC increased its stake in shares of Fulcrum Therapeutics by 62.1% in the 1st quarter. Jane Street Group LLC now owns 117,816 shares of the company’s stock worth $339,000 after acquiring an additional 45,157 shares during the last quarter. Exome Asset Management LLC increased its stake in shares of Fulcrum Therapeutics by 143.0% in the 1st quarter. Exome Asset Management LLC now owns 689,137 shares of the company’s stock worth $1,985,000 after acquiring an additional 405,538 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Fulcrum Therapeutics in the 1st quarter worth $425,000. Finally, ADAR1 Capital Management LLC increased its stake in shares of Fulcrum Therapeutics by 150.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 490,532 shares of the company’s stock worth $1,413,000 after acquiring an additional 294,284 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.